View clinical trials related to Solid Neoplasms.
Filter by:The primary purpose of the study is to evaluate safety and tolerability and to determine recommended Phase 2 dose (RP2D) of E7389-LF in combination with nivolumab in Phase 1b part, and to evaluate objective response rate (ORR) of E7389-LF and nivolumab using RP2D in Phase 2 part in each tumor type.
The primary objective of this study is to assess the safety and tolerability of E7386 in participants with solid tumor including CRC.